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Abstract:  More  than  30  million  persons  worldwide  take  nonsteroidal  anti-inflammatory  drugs
(NSAIDs)  on  a  daily  basis,  and  annual  consumption  is  increasing.  In  addition  to  their  analgesic  and
anti-inflammatory  properties,  NSAIDs  also  produce  well-known  gastrointestinal  adverse  events.
There is  no  consensus  in  Mexico  on  the  diagnosis,  treatment,  and  prevention  of  NSAID-induced
gastropathy  and  enteropathy,  and  so  the  Asociación  Mexicana  de  Gastroenterología  brought
together a  group  of  experts  to  establish  useful  recommendations  for  the  medical  community.
Thirty-three  recommendations  were  formulated  in  the  present  consensus,  highlighting  the  fact
that the  risk  for  NSAID-induced  gastrointestinal  toxicity  varies  according  to  the  drug  employed
and its  pharmacokinetics,  which  should  be  taken  into  account  at  the  time  of  prescription.
The risk  factors  for  gastroduodenal  complications  due  to  NSAIDs  are:  a  history  of  peptic  ulcer,
age above  65  years,  high  doses  of  NSAIDs,  Helicobacter  pylori  infection,  and  the  presence
of severe  comorbidities.  The  symptoms  and  gastroduodenal  damage  induced  by  NSAIDs  vary,
ranging from  an  asymptomatic  course  to  the  presentation  of  iron-deficiency  anemia,  bleeding,
stricture,  and  perforation.  Capsule  endoscopy  and  enteroscopy  are  direct  diagnostic  meth-
ods in  NSAID  enteropathy.  Regarding  prevention,  the  minimum  dose  of  an  NSAID  needed  to
achieve the  desired  effect,  administered  for  the  shortest  period  of  time,  is  the  recommenda-
tion. Finally,  proton  pump  inhibitors  are  the  gold  standard  for  the  prophylaxis  and  treatment
of gastroduodenal  effects,  but  they  are  not  useful  in  enteropathy.
© 2020  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Consenso  mexicano  sobre  diagnóstico,  prevención  y  tratamiento  de  la  gastropatía  y
enteropatía  por  antiinflamatorios  no  esteroideos
Resumen  Más  de  30  millones  de  personas  consumen  diariamente  antiinflamatorios  no
esteroideos  (AINE)  en  el  mundo,  y  este  consumo  se  ve  incrementado  anualmente.  Aunque  los
AINE poseen  propiedades  analgésicas  y  antiinflamatorias,  sus  eventos  adversos  gastrointesti-
nales son  bien  reconocidos.  En  nuestro  país  no  existía  un  consenso  respecto  al  diagnóstico,
tratamiento  y  prevención  de  la  gastropatía  y  la  enteropatía  por  AINE,  por  lo  que  la  Asociación
Mexicana  de  Gastroenterología  reunió  a  un  grupo  de  expertos  para  establecer  recomendaciones
de utilidad  para  la  comunidad  médica.  En  este  consenso  se  emitieron  33  recomendaciones.  El
consenso destaca  que  el  riesgo  de  toxicidad  gastrointestinal  de  los  AINE  varía  según  el  fármaco
empleado  y  su  farmacocinética,  lo  cual  debe  ser  considerado  al  momento  de  su  prescripción.  Los
factores de  riesgo  de  complicación  gastroduodenal  por  AINE  son:  antecedente  de  úlcera  pép-
tica, edad  mayor  a  65  an˜os,  dosis  altas  del  AINE,  infección  por  Helicobacter  pylori  (H.pylori),  y
presencia de  comorbilidades  graves.  Los  síntomas  y  el  dan˜o  gastroduodenal  inducido  por  AINE
son variables  ya  que  puede  cursar  asintomático  o  manifestarse  como  anemia  por  deficiencia  de
hierro, hemorragia,  estenosis  y  perforación.  La  cápsula  endoscópica  y  la  enteroscopia  son  méto-
dos diagnósticos  directos  en  la  enteropatía  por  AINE.  Respecto  a  la  prevención,  se  recomienda
prescribir la  dosis  mínima  necesaria  de  un  AINE  para  obtener  el  efecto  deseado  y  durante  el
menor tiempo.  Finalmente,  los  inhibidores  de  la  bomba  de  protones  (IBP)  representan  el  están-
dar de  oro  para  la  profilaxis  y  tratamiento  de  los  efectos  gastroduodenales,  mas  no  son  útiles
en la  enteropatía.
©  2020  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1 M.V.  Bielsa-Fernández  et  al.
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Table  1  GRADE  system  codes.
Quality  of  evidence  Code
  High  A
 Moderate B  C
 Low D
  Very  low
Strength  of  recommendation
  Strong,  in  favor  of  the  intervention  1
 Weak,  in  favor  of  the  intervention 2
  Weak,  against  the  intervention 2
 Strong,  against  the  intervention 1
Source: Adapted from Guyat et al.3.
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ntroduction
ore  than  30  million  persons  worldwide  take  nonsteroidal
nti-inflammatory  drugs  (NSAIDs)  on  a  daily  basis.1 Said  use
s  increasing  yearly  due  to  the  greater  life  expectancy  of
he  population  and  the  self-prescription  of  aspirin  and  other
SAIDs.  In  addition  to  their  excellent  analgesic  and  anti-
nflammatory  properties,  NSAIDs  also  produce  well-known
astrointestinal,  cardiovascular,  renal,  and  hepatic  adverse
vents.  The  most  frequent  NSAID-related  adverse  events  are
astrointestinal,  and  they  result  in  greater  morbidity  and
ortality.
In  February  2018,  the  Asociación  Mexicana  de  Gastroen-
erología  brought  together  a  multidisciplinary  group  of
ealth  professionals  made  up  of  gastroenterologists,  endo-
copists,  and  surgeons  to  produce  The  Mexican  Consensus  on
he  Diagnosis,  Treatment,  and  Prevention  of  NSAID-induced
astropathy  and  Enteropathy  and  establish  useful  recom-
endations  for  the  medical  community.  The  specific  aim  of
he  consensus  was  to  prepare  an  updated  document  appli-
able  to  medical  practice  in  Mexico.  The  recommendations
ncluded  are  based  on  a  thorough  review  of  the  medical
iterature  and  the  consensus  opinion  of  the  participating
pecialists.
ethods
he  consensus  was  developed  using  the  Delphi  process,
s  has  been  previously  described.2 Three  coordinators
MVBF,  JLL,  JLT  de  la  C)  were  designated  and  20  experts
n  specialties  related  to  NSAID-induced  gastropathy  and
nteropathy  were  invited  to  participate.  The  coordi-
ators  carried  out  a  detailed  search  of  the  following
atabases:  The  Cochrane  Central  Register  of  Controlled
rials  (CENTRAL),  MEDLINE  (PubMed),  EMBASE  (Ovid),
ILACS,  CINAHL,  BioMed  Central,  and  the  International
linical  Trials  Registry  Platform  (ICTRP)  of  the  World
ealth  Organization.  The  search  encompassed  articles
ublished  within  the  time  frame  of  January  1,  2008
o  February  28,  2018.  The  search  criteria  included  the
erm:  ‘‘nonsteroidal  anti-inflammatories’’  combined
ith  the  following  terms:  ‘‘gastric’’,  ‘‘small  bowel’’,
‘enteropathy’’,  ‘‘risk’’  ‘‘incidence’’,  ‘‘prevalence’’,
‘Mexico’’,  ‘‘pathophysiology’’,  ‘‘diagnosis’’,  ‘‘differential
iagnosis’’,  ‘‘treatment’’,  ‘‘endoscopy’’,  ‘‘therapy’’,
‘management’’,  ‘‘review’’,  ‘‘guidelines’’,  and  ‘‘meta-
nalysis’’  and  their  Spanish  equivalents.  The  complete
ibliography  was  made  available  to  all  the  consensus
articipants.
The  coordinators  then  formulated  statements  that  under-
ent  a  first  round  of  anonymous,  electronic  voting  (from
ebruary  2  to  11,  2018)  to  evaluate  the  drafting  and  content
f  the  statements.  The  consensus  participants  voted  utiliz-
ng  the  following  responses:  a)  in  complete  agreement,  b)  in
artial  agreement,  c)  uncertain,  d)  in  partial  disagreement,
nd  e)  in  complete  disagreement.
After  the  first  vote,  the  coordinators  carried  out  the
orresponding  modifications.  Statements  in  which  com-
lete  agreement  was  >75%  were  kept,  and  those  in  which
omplete  disagreement  was  >  75%  were  eliminated.  The
tatements  with  complete  agreement  ≤  75%  and  complete
o
m
m
aisagreement  ≤75%  were  reviewed  and  restructured.  The
evised  statements  underwent  a  second  anonymous,  elec-
ronic  round  of  voting  (from  February  11  to  March  4,  2018)
fter  the  second  vote,  in  addition  to  drafting  and  content,
ach  statement  was  evaluated  according  to  the  quality  of
vidence  and  grade  of  recommendation  that  sustained  it,
hich  was  done  through  the  Grading  of  Recommendations
ssessment,  Development,  and  Evaluation  (GRADE)  system.3
n  the  GRADE  system,  the  quality  of  evidence  is  not  graded
ased  solely  on  the  design  or  methodology  of  the  research,
ut  also  on  a clearly  posed  question  related  to  an  outcome
hat  is  also  clearly  stated.4 Thus,  evidence  is  described  as
igh,  moderate,  low,  or  very  low,  and  the  strength  of  rec-
mmendation  is  strong  or  weak  and  in  favor  of  or  against
he  intervention  or  statement.  Importantly,  the  GRADE  sys-
em  was  used  in  relation  to  diagnostic  tests  and  therapeutic
nterventions.  Table  1  shows  the  codes  utilized  in  the  GRADE
ystem,  in  which  upper  case  letters  refer  to  the  quality  of
vidence,  followed  by  a  number  indicating  the  strength  of
he  recommendation  that  is  in  favor  of  or  against  the  inter-
ention  or  statement.
The  results  of  the  third  voting  round  were  presented  on
pril  14,  2018,  at  a  face-to-face  meeting  held  in  the  city  of
urango  (Durango,  Mexico).  At  that  meeting,  the  statements
n  which  agreement  was  >  75%  were  ratified.  The  statements
hat  did  not  reach  agreement  of  75%  in  the  previous  voting
ounds  were  discussed,  in  an  effort  to  reach  a  consensus.
f  no  consensus  was  reached,  they  were  eliminated.  A  final
ote  was  then  carried  out.  Once  all  the  consensus  state-
ents  were  established,  the  coordinators  formulated  the
resent  manuscript,  which  was  reviewed  and  approved  by
ll  the  consensus  members.
esults
nitially,  the  coordinators  proposed  39  statements.  After  the
nline  rounds  of  voting  and  the  final  vote  at  the  face-to-face
eeting,  the  resultant  consensus  was  made  up  of  33  recom-
endations.  The  final  recommendations  and  voting  results
re  presented  below.
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Generalities and risk factors
1.-  Nonsteroidal  anti-inflammatory  drugs  (NSAIDs)  are  one
of  the  most  commonly  used  over-the-counter  medications
worldwide.
Agreement  reached:  90%  in  total  agreement,  10%  in  par-
tial  agreement.
NSAIDs  are  drugs  that  reduce  pain,  fever,  and  inflamma-
tion,  and  are  currently  classified  as1,5:
a)  Nonselective  NSAIDs  (nsNSAIDs),  such  as  naproxen,
indomethacin,  ibuprofen,  sulindac,  diclofenac,  and
piroxicam.
b)  Selective  cyclo-oxygenase-2  inhibitors  (selective  COX-2
inhibitors),  which  include  the  coxibs  (such  as  rofe-
coxib,  etoricoxib,  and  celecoxib)  and  the  so-called
‘‘preferential’’  inhibitors,  such  as  nimesulide  and
meloxicam.
Due  to  the  increasing  life  expectancy  of  the  worldwide
population  and  the  corresponding  increase  in  rheumato-
logic  disorders,  NSAID  use  has  substantially  risen  in  recent
decades.1 In  addition  to  the  anti-inflammatory,  analgesic,
and  antipyretic  effects  of  acetylsalicylic  acid  (ASA),  its  use
in  low  doses  is  employed  to  reduce  the  risk  for  ischemic  car-
diac  and  cerebrovascular  events.  That  indication  has  been
popularized  and  many  persons  use  it  with  no  medical  pres-
cription  or  exact  indication.1,5 At  least  in  the  United  States,
those  medications  are  the  most  widely  used,  either  as  pres-
cription  or  over-the-counter  drugs.6 There  has  also  been
an  increase  in  the  clinical  application  of  NSAIDs  as  prophy-
lactic  drugs  against  neoplasias  or  as  part  of  the  treatment
of  Alzheimer’s  disease.7 Thus,  it  is  likely  for  NSAID-induced
enteropathy  to  be  increasingly  diagnosed.
2.-  NSAID-induced  gastroduodenopathy  is  due  to  a  sys-
temic  effect  that  causes  hypoperfusion  and  a  reduction
in  bicarbonate  synthesis  and  epithelial  proliferation,  sec-
ondary  to  prostaglandin  synthesis  inhibition,  as  well  as  to
direct  topical  effects  that  cause  disruption  of  the  cyto-
protective  barrier  of  the  mucosa.
Agreement  reached:  80%  in  total  agreement,  20%  in  par-
tial  agreement.
The harmful  effect  of  NSAIDs  on  the  gastroduodenal
mucosa  is  mediated  by  2  mechanisms.  The  main  one  is  the
systemic  effect,  which  is  due  to  the  inhibition  of  cyclo-
oxygenase  (COX)  activity,  causing  less  blood  flow,  reduced
bicarbonate  and  prostaglandin  synthesis,  and  a  decrease
in  epithelial  proliferation.8 They  can  also  cause  topical
mucosal  damage,  resulting  in  the  disruption  of  the  gastric
mucosal  barrier,  by  action  of  the  nonionized  weak  acids
inside  the  cells,  causing  intracellular  alterations  in  the
mitochondria  due  to  uncoupling  of  mitochondrial  oxidative
phosphorylation,  as  well  as  damage  to  the  lipid  bilayer.9,10
That  direct  cytotoxicity  is  independent  of  COX  inhibition  and
causes  an  increase  in  membrane  permeability,  resulting  in
epithelial  damage  with  additional  necrosis  and  apoptosis  of
the  gastric  cells.113.-  The  pathophysiology  of  NSAID-induced  enteropathy
is  different  from  that  of  gastroduodenopathy.
Agreement  reached:  70%  in  total  agreement,  30%  in  par-
tial  agreement.
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The  pathogenesis  of  intestinal  lesions  induced  by  NSAIDs
s  less  understood  than  that  of  gastroduodenopathy.9 Ulcers
ypically  present  as  necrotic  (or  apoptotic)  damage  of  ente-
ocytes  that  can  affect  the  deepest  layers  of  the  mucosa,
ith  acute  inflammatory  infiltrate  and  loss  of  the  villi.9
nlike  gastroduodenopathy,  the  symptoms  of  NSAID-induced
nteropathy  are  nonspecific  and  its  pathophysiology  appears
o  be  different.  However,  the  damage  induced  by  nsNSAIDs
nd  selective  COX-2  inhibitors  is  similar  in  the  small  bowel.
or  example,  a study  showed  there  was  no  difference  in
elation  to  intestinal  lesions  induced  by  long-term  use  of
sNSAIDs  or  selective  COX-2  inhibitors  (62  vs.  50%).12 Sev-
ral  years  ago,  the  3-hit  hypothesis  was  posited:  first,  the
SAID  affects  the  phospholipids  of  the  cell  membrane,  resul-
ing  in  mitochondrial  injury.  That  causes  the  second  hit,
hich  is  the  decrease  in  the  synthesis  of  energy,  resulting
n  the  release  of  calcium  and  the  production  of  free  radi-
als.  Consequently,  the  intercellular  bonds  are  broken,  and
he  permeability  of  the  mucosa  increases.  The  third  hit  is
hen  produced,  in  which  the  intraluminal  content,  such  as
he  bile  acids,  proteolytic  enzymes,  and  gut  bacteria  and
heir  toxins,  enter  the  cells  and  inflammation  begins.13,14
t  present,  there  is  no  evidence  that  the  suppression  of
astric  acid  secretion  reduces  the  incidence  or  severity  of
SAID-induced  enteropathy.  In  fact,  the  few  studies  on  the
heme  indicate  that  the  benefit  is  marginal,  and  studies
onducted  on  animals  suggest  that  the  concomitant  use  of
roton  pump  inhibitors  (PPIs)  and  NSAIDs  exacerbate  the
xisting  enteropathy  and  that  said  damage  appears  to  be
elated  to  changes  in  the  number  and  type  of  bacteria  in
he  small  bowel  during  therapy  with  PPIs.15
4.-  NSAID-induced  damage  along  the  gastrointestinal
ract  is  greater,  with  the  concomitant  use  of  other  NSAIDS,
nticoagulants,  and  antiplatelet  drugs.
Agreement  reached:  85%  in  total  agreement,  15%  in  par-
ial  agreement.
Antiplatelet  agents  and  anticoagulants  per  se  carry  a
isk  for  gastrointestinal  complications  (ulceration  or  bleed-
ng)  and  the  risk  increases  with  the  concomitant  use  of
SAIDs  and  other  medications  (statements  8  through  12).
herefore,  communication  between  cardiologists,  gastroen-
erologists,  and  primary  care  physicians  is  essential  for
ndividually  evaluating  the  risk  for  ischemic  or  bleeding
vents  in  the  patient  requiring  those  medications.16
5.-  The  risk  for  gastrointestinal  toxicity  from  different
SAIDs  varies,  depending  on  the  drug  employed  and  its
harmacokinetics,  which  should  be  taken  into  considera-
ion  at  the  time  of  prescription.
Agreement  reached:  95%  in  total  agreement,  5%  in  par-
ial  agreement.
It is  well  known  that  all  NSAIDs,  albeit  to  greater  or
esser  degrees,  cause  gastrointestinal  toxicity.  Numerous
ontrolled  clinical  trials  with  placebo  demonstrate  that  all
SAIDs,  including  the  selective  COX-2  inhibitors,  are  associ-
ted  with  a  higher  or  lower  risk  for  gastrointestinal  lesions,
nd  the  relative  risk  varies  among  the  different  NSAIDs.  The
elative  risk  for  aceclofenac,  celecoxib,  and  ibuprofen  is
ow  (relative  risk  [RR]  <  2).17 Diclofenac,  meloxicam,  and
etoprofen  have  an  intermediate  risk  (RR  =  2-4),  whereas  for
aproxen,  indomethacin,  and  diflunisal,  the  risk  is  higher
RR  =  4-5).  Piroxicam  (RR  =  7.4)  and  ketorolac  (RR  =  11.5)
1 M.V.  Bielsa-Fernández  et  al.
a
t
t
t
m
e
L
b
a
i
m
u
h
t
g
c
f
d
r
c
c
d
T
N
p
w
i
f
t
a
t
t
a
n
a
b
a
r
n
E
i
t
e
b
n
p
d
U
8
t
5
p
c
c
d
H
e
Table  2  Risk  factors  for  gastrointestinal  complications
associated  with  NSAID  intake.
Gastroduodenopathy  risk  factor  Relative  risk
Age  ≥  65  years  4.7
NSAID at  high  doses 8.0
History  of  peptic  ulcer  13.5
Use of  two  or  more  NSAIDs  4.1
Concomitant  therapy
Anticoagulants  12.7
Serotonin  reuptake  inhibitors  6.33
Antiplatelet  drugs  3.66
Corticosteroids  4.4
Severe comorbidities
Cardiovascular  disease  1.8
Kidney disease  1.27
Helicobacter  pylori  infection  3.5
Helicobacter  pylori  infection  +  NSAID  20.8
Type of  NSAID
Aceclofenac,  ibuprofen,  celecoxib  <2
Rofecoxib,  meloxicam,  nimesulide,
sulindac,  diclofenac,  ketoprofen
2  --  4
Tenoxicam,  naproxen,
indomethacin,  diflunisal
4  --  5
Piroxicam,  azapropazone,
ketorolac
>  5
Enteropathy  risk  factor
Age  ≥  65  years  4.16
NSAID +  H2  receptor  antagonist  3.95
NSAID +  PPI  5.22
COXIB +  PPI  2.7
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re  the  drugs  that  have  a  greater  risk  for  gastrointestinal
oxicity.17
The  manner  in  which  to  prevent  NSAID-induced  lesions  of
he  gastrointestinal  mucosa  is  to  avoid  their  use  or  substitute
hem  with  an  agent  that  is  less  toxic  for  the  gastrointestinal
ucosa,  such  as  acetaminophen.  But  if  NSAID  use  is  nec-
ssary,  an  effort  should  be  made  to  minimize  damage.18
ower  effective  doses  should  be  searched  for,  they  should
e  used  for  the  least  amount  of  time  possible,  and  prefer-
bly  only  the  same  NSAID  should  be  used.  Selective  COX-2
nhibitors  should  also  be  given  preference,  if  there  are  no
ajor  cardiovascular  risks,  or  a  safer  nsNSAID  should  be
sed,  such  as  ibuprofen,  diclofenac,  or  aceclofenac,  which
ave  been  associated  with  a  lower  relative  risk  for  gastroin-
estinal  bleeding.18,19 Selective  COX-2  inhibitors  have  lower
astroduodenal  toxicity,  compared  with  nsNSAIDs.  The  main
oncern  with  their  use  is  their  association  with  greater  risk
or  cardiovascular  events,  but  many  nsNSAIDs,  particularly
iclofenac,  have  also  been  associated  with  cardiovascular
isk.17--19 On  the  other  hand,  the  risk  for  gastrointestinal
omplications  increases  if  high  doses  of  NSAIDs  are  used  in  a
ontinuous  manner.  That  risk  is  constant,  regardless  of  the
ose,  and  for  the  entire  time  the  treatment  is  maintained.20
hus,  different  drug  regulatory  agencies  recommend  that  all
SAIDs  be  used  at  the  minimum  dose,  for  the  shortest  time
eriod  possible,  and  in  accordance  with  the  indication  for
hich  it  was  prescribed.21,22
6.-  Nonselective  NSAIDs  and  selective  COX-2  inhibitors
nduce  damage  throughout  the  intestine  with  the  same
requency.
Agreement  reached:  55%  in  total  agreement,  25%  in  par-
ial  agreement,  20%  uncertain.
Compared  with  nsNSAIDs,  selective  COX-2  inhibitors  are
ssociated  with  a  significantly  lower  risk  for  damage  at
he  gastroduodenal  level  but  not  at  the  distal  gastroin-
estinal  level  (middle  intestine  and  colon),  where  the  risk
ppears  to  be  similar.  There  is  increasing  evidence  of  a
otable  rise  in  small  bowel  lesions.  NSAID-induced  lesions
nd  their  complications  in  the  stomach  and  duodenum  have
een  known  about  for  many  years.  With  the  increased  avail-
bility  of  endoscopic  equipment,  they  have  become  more
ecognized  and  more  easily  identified,  but  the  actual  mag-
itude  of  damage  in  the  distal  digestive  tract  is  unknown.23
nteropathy  is  often  underdiagnosed  or  even  undetected
n  the  majority  of  studies,  because  the  lesions  are  beyond
he  reach  of  conventional  endoscopic  examination.  Nev-
rtheless,  an  increasing  number  of  hospitalizations  are
eing  reported  for  complications  in  the  lower  gastrointesti-
al  tract.24 Some  reports  in  the  literature  state  that  the
revalence  of  enteropathy  is  greater  than  that  of  gastroduo-
enopathy  and  that  the  serious  complications  are  similar.25
lcerations  in  the  small  bowel  were  detected  in  autopsies  of
.4%  of  the  subjects  that  took  NSAIDs,  compared  with  0.6%  of
he  subjects  that  never  took  them.26 In  another  study,  from
5  to  75%  of  the  patients  treated  continuously  with  NSAIDs
resented  with  damage  in  the  intestinal  mucosa.27
7.-  Risk  factors  for  NSAID-induced  gastroduodenal
omplications  are:  a)  a  history  of  peptic  ulcer  (compli-
ated  or  uncomplicated),  b)  age  above  65  years,  c)  high
oses  of  NSAIDs,  d)  concomitant  use  of  medications,  e)
elicobacter  pylori  (H.  pylori) infection,  and  f)  the  pres-
nce  of  severe  comorbidities.
t
(Source: Modified from Lanza et al.103.
Agreement  reached:  90%  in  total  agreement,  10%  in  par-
ial  agreement.
The most  important  risk  factors  are  age  and  a  pre-
ious  history  of  peptic  ulcer  (Table  2).  NSAIDs  are  more
requently  used  in  older  patients,  and  the  risk  in  patients
bove  70  years  of  age  is  similar  to  that  of  patients  with
 history  of  peptic  ulcer.  As  age  increases,  risk  increases
bout  4%  annually,  probably  due  to  the  presence  of  other
ssociated  risk  factors.19 The  role  of  H.  pylori  infection
nd  the  potential  benefit  of  its  eradication  in  patients  that
ake  nsNSAIDs  has  been  controversial.9,19 A  meta-analysis
f  case-control  studies  demonstrated  synergism  between  H.
ylori  infection  and  NSAID  use  for  the  development  of  com-
licated  and  uncomplicated  ulcers  (statement  31).28 ASA,
teroids,  antithrombotics,  and  more  recently,  selective  sero-
onin  reuptake  inhibitors  (SSRIs),  as  mentioned  in  statement
,  are  among  the  medications  associated  with  an  increased
isk  of  gastrointestinal  toxicity  from  NSAID  intake.29 Severe
omorbidities  (e.g.  neoplasias,  severe  heart  diseases,  kid-
ey  failure,  etc.)  are  also  considered  risk  factors.30
8.-  Concomitant  intake  of  nsNSAIDs  and  selective
OX-2  inhibitors  can  predispose  to  the  development  of
astrointestinal  complications.
Agreement  reached:  75%  in  total  agreement,  20%  in  par-
ial  agreement,  5%  uncertain.
The  simultaneous  use  of  2  or  more  different  NSAIDs
selective  or  nonselective)  is  not  recommended  because
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that  strategy  does  not  increase  their  analgesic,  anti-
inflammatory,  or  antipyretic  efficacy,  but  does  increase  the
risk  for  gastrointestinal  toxicity  and  its  complications.20 Evi-
dence  from  animal  studies  demonstrates  a  cytoprotective
role  of  prostanoids  in  the  gastrointestinal  tract,  derived
from  the  two  COX  isoenzymes.  Prostanoids  derived  from
COX-1  (basically  prostaglandin-E2)  participate  as  a  defense
mechanism  that  acts  on  physiologic  conditions.  In  contrast,
endogenous  prostaglandin-E2  derived  from  COX-2  plays  an
important  role  in  the  healing  of  ulcers  and  the  repair  of
the  gastroduodenal  mucosa.  Thus,  the  inhibition  of  either
of  the  two  COX  isoenzymes  predisposes  to  the  development
of  lesions  in  the  gastrointestinal  tract.31
9.-  The  concomitant  use  of  ASA  with  nsNSAIDs  or  selec-
tive  COX-2  inhibitors,  even  at  low  doses,  increases  the  risk
for  gastrointestinal  symptoms  and  complications.
Agreement  reached:  90%  in  total  agreement,  10%  in  par-
tial  agreement.
Many patients  that  take  NSAIDs  also  require  antithrom-
botic  prophylaxis  with  ASA.  ASA,  even  at  low  doses,
increases  the  risk  for  gastrointestinal  bleeding  by  2.5
times,  and  increases  the  risk  for  upper  gastrointestinal
complications  when  combined  with  an  nsNSAID  or  selective
COX-2  inhibitor.
Aspirin  alone,  at  low  doses,  increases  the  risk  for  upper
gastrointestinal  bleeding  (UGIB)  by  approximately  2  times.
When  combined  with  an  nsNSAID,  that  risk  increases  2  to
4  times,  compared  with  low  doses  of  ASA.32 The  combina-
tion  of  low  doses  of  ASA  with  selective  COX-2  inhibitors  is
associated  with  a  numerical,  but  not  significant,  decrease
in  bleeding,  compared  with  the  combination  with  nsN-
SAIDs.  On  the  other  hand,  hospital  admissions  for  UGIB
are  significantly  fewer  in  ASA  users  that  are  also  taking
selective  COX-2  inhibitors,  compared  with  those  that  are
taking  nsNSAIDs.33 When  a  selective  COX-2  inhibitor  is  co-
administered  with  aspirin,  the  conversion  of  arachidonic
acid  to  15  (r)  hydroxyepitetraenoic  acid  (and,  in  turn,  the
production  of  gastroprotective  lipoxin,  15  [r]-EPI-lipoxin
A4)  is  blocked,  resulting  in  gastric  damage  that  is  more
severe  than  that  seen  with  aspirin  alone,  or  combined  with
a  selective  COX-2  inhibitor.14 In  clinical  practice,  selec-
tive  COX-2  inhibitor  use  reduces,  but  does  not  eliminate,
the  risk  for  gastroduodenal  lesions.  However,  that  poten-
tial  benefit  is  lost,  when  combined  with  ASA,  even  at  low
doses.34
There  is  a  lower  risk  for  UGIB  with  the  use  of  selec-
tive  COX-2  inhibitors  than  with  nsNSAIDs,  but  when  they
are  combined  with  low  doses  of  ASA,  the  differences
between  nsNSAIDs  and  selective  COX-2  inhibitors  tend  to
disappear.34,35 Treatment  with  antiplatelet  agents  (ASA  or
others)  involves  a  similar  risk  for  causing  UGIB.  Lanas  et  al.35
found  that  NSAID  use  increased  the  risk  for  UGIB  (RR  =  5.3),
as  did  treatment  with  rofecoxib  (RR  =  2.1),  but  the  use  of
celecoxib,  paracetamol,  or  the  concomitant  use  of  a  PPI
with  an  NSAID,  did  not  present  a  greater  risk.  Antiplatelet
treatment  with  clopidogrel  or  ticlopidine  had  a  risk  for
UGIB  (RR  =  2.8)  similar  to  that  of  ASA  at  a  cardio-protective
dose  (100  mg/day)  (RR  =  2.7)  or  to  that  of  anticoagulants
(RR  =  2.8).  Nevertheless,  an  obvious  interaction  was  found
between  the  use  of  low-dose  ASA  with  NSAIDs,  selective
COX-2  inhibitors,  or  thienopyridines,  and  an  even  higher  risk
for  UGIB.35
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10.-  The  risk  for  upper  gastrointestinal  bleeding  (UGIB)
ncreases  with  the  prescription  of  clopidogrel  plus  ASA,
ompared  with  ASA  alone.
Agreement  reached:  85%  in  total  agreement,  5%  in  par-
ial  agreement,  10%  uncertain.
The  risk  for  gastrointestinal  bleeding  with  the  use  of  ASA
ncreases  even  more  with  the  concomitant  prescription  of
lopidogrel.  Clopidogrel  is  often  perceived  to  be  relatively
afe  in  terms  of  gastrointestinal  adverse  events,  but  data
how  that,  even  as  monotherapy,  clopidogrel  is  associated
ith  a  high  risk  for  rebleeding  in  patients  with  a  previous
istory  of  bleeding  due  to  peptic  ulcer.  When  clopidogrel
s  combined  with  ASA,  the  risk  for  bleeding  increases  even
ore.16
Three  large  controlled  clinical  trials  have  evaluated  the
ombination  of  clopidogrel  and  ASA,  compared  with  ASA
lone:  CURE,36 COMMIT,37 and  CHARISMA.38 The  first  analysis
ound  a  significantly  higher  risk  for  bleeds  over  a  12-month
eriod,  whereas  the  CHARISMA  study38 reported  a  higher  risk
or  moderate  bleeding  and  an  increase,  albeit  not  signifi-
ant,  in  the  risk  for  severe  bleeding  over  a period  of  more
han  28  months  with  the  combination,  compared  with  ASA
lone,  but  the  mean  treatment  duration  was  only  15  days.
hus,  for  patients  at  high  risk  for  gastrointestinal  bleeding,
he  recommendation  is  to  avoid  the  combination  of  clopido-
rel  and  ASA.
11.-  H.  pylori  eradication  prevents  the  recurrence  of
eptic  ulcer  in  NSAID  users.
Agreement  reached:  75%  in  total  agreement,  20%  in  par-
ial  agreement,  5%  in  partial  disagreement.
The  role  that  H.  pylori  infection  plays  in  the  develop-
ent  of  peptic  ulcer  is  clear,  and  according  to  the  Mexican
onsensus  on  the  diagnosis  and  treatment  of  H.  pylori  in
exico  and  numerous  meta-analyses,  the  eradication  of  that
acterium  is  known  to  significantly  reduce  the  risk  for  ulcers
statement  31).28,39 Nevertheless,  several  clinical  trials  have
hown  that  the  concomitant  treatment  of  NSAIDs  with  PPIs
an  be  superior  to  preventive  eradication  of  that  microor-
anism,  in  relation  to  peptic  ulcer  prevention  (primary  and
econdary).32 Thus,  the  decision  to  prescribe  eradication
reatment  depends  on  the  local  prevalence  of  the  infection
nd  other  particular  risk  factors  that  each  individual  can
resent  with,  as  described  in  the  Mexican  consensus  on  the
iagnosis  and  treatment  of  H.  pylori  infection  in  Mexico.39
12.-  The  risk  for  upper  gastrointestinal  bleeding
ncreases  with  the  concomitant  use  of  NSAIDs  and  selec-
ive  serotonin  reuptake  inhibitors.
Agreement  reached:  80%  in  total  agreement,  20%  in  par-
ial  agreement.
There is  recent  concern  about  the  use  of  SSRIs,  given  that
tudies  have  shown  they  can  be  associated  with  a  higher
isk  for  UGIB,  and  that  risk  can  increase  even  more  if  they
re  used  with  an  NSAID.  Published  reports,  from  a relatively
mall  number  of  studies,  have  stated  there  is  a  substantial
isk  for  gastrointestinal  bleeding  with  SSRI  use.  However,
ore  recent  studies  have  produced  varying  results.
A  more  recent  meta-analysis  aimed  to  provide  a  more
ccurate  estimate  of  the  risk  for  UGIB  with  SSRIs,  with
r  without  concurrent  NSAID  use.  The  authors  analyzed  15
ase-control  studies  (including  393,268  participants)  and  4
ohort  studies.40 There  was  a  greater  risk  for  UGIB  with  SSRI
edications  in  the  2  types  of  studies,  with  odds  ratios  (ORs)
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hat  varied  from  1.66  to  1.68.  The  number  necessary  to  harm
for  UGIB)  with  SSRI  use  in  a  low-risk  population  was  3.177
nd  in  a  high-risk  population  was  8.81.  The  risk  for  UGIB
ncreased  even  more,  with  the  concomitant  use  of  SSRIs  and
SAIDs  (OR  =  4.25,  95%  CI  =  2.82-6.42).  Those  authors  con-
luded  that  SSRIs  were  associated  with  a  modest  increase
n  the  risk  for  UGIB,  which  was  lower  than  that  previously
stimated.
Therefore,  the  participants  in  the  present  consensus  con-
ider  that  caution  must  be  employed  when  prescribing  the
ombination  of  those  2  types  of  medications.
linical  manifestations  and  diagnosis
3.-  Symptoms  and  gastroduodenal  damage  induced  by
SAIDs  are  broad  and  varied.
Agreement  reached:  85%  in  total  agreement,  15%  in  par-
ial  agreement.
The damage  caused  to  the  digestive  tract  by  NSAIDs,
egardless  of  their  administration  route  (topical  or  sys-
emic),  is  broad,  varying  from  the  presence  of  dyspeptic
ymptoms,  heartburn,  and  nausea,  to  the  presence  of  com-
licated  or  uncomplicated  peptic  ulcers.24,41 Importantly,
he  presence  and  intensity  of  those  symptoms  do  not  pre-
ict  the  presence  of  mucosal  lesions.24 For  example,  50%
f  NSAID  users  have  symptoms  and  no  mucosal  lesion,
nd  50%  of  patients  with  complicated  peptic  ulcer  have
eported  no  previous  symptoms.30 On  the  other  hand,  in
he  United  States,  up  to  25%  of  NSAID  users  develop  peptic
lcer  and  2-4%  present  with  the  complications  of  perfora-
ion  or  bleeding.42 The  development  of  those  symptoms  is
ot  exclusive  to  nsNSAIDs,  given  that  they  have  also  been
emonstrated  with  selective  COX-2  inhibitor  use,  albeit  in
maller  numbers.43
Importantly,  the  period  of  greater  risk  for  developing
ymptoms  and/or  complications  is  apparently  in  the  first
onth  of  use  (OR  =  5.7).44 Other  studies  have  shown  the
rst  2  months  of  use  to  be  the  period  of  greater  risk  for
omplications,  but  the  risk  is  maintained  over  the  period
f  time  the  drugs  are  taken.35,45 Approximately  47/100,000
SAID  users  are  estimated  to  require  hospitalization  due  to
dverse  upper  gastrointestinal  tract  events,  with  a  mortality
ate  associated  with  severe  gastrointestinal  complications  of
.57%.46,47
14.-  The  course  of  NSAID-induced  enteropathy  is  fre-
uently  asymptomatic  but  can  also  manifest  as  iron
eficiency  anemia,  bleeding,  stricture,  and  perforation.
Agreement  reached:  100%  in  total  agreement.
There  are  increasingly  more  reports  of  harmful  effects
f  NSAIDs  on  the  lower  digestive  tract  that  lead  to  sig-
ificant  morbidity  and  mortality.48 The  adverse  events
nclude  increased  mucosal  permeability,  inflammation  of
he  mucosa,  protein  loss,  malabsorption,  bleeding  or  occult
leeding,  diarrhea,  ulcers,  stricture,  and  perforation.49
ecognition  of  the  toxic  effects  of  NSAIDs  on  the  lower  gas-
rointestinal  tract  has  increased  with  the  advent  of  new
echnologies  for  evaluating  intestinal  integrity,  especially
ith  capsule  endoscopy  and  enteroscopy.50 The  damage
aused  by  NSAIDs  in  not  transitory,  nor  does  it  decrease
ver  time.  For  example,  with  continuous  use,  at  3  months  of
SAID  consumption,  71%  of  users  had  mucosal  lesions  and  up
-
-M.V.  Bielsa-Fernández  et  al.
o  80%  had  them  at  one  year.51,52 Through  capsule  endoscopy,
ndo  et  al.53 showed  that  inflammation  of  the  intestinal
ucosa  could  be  caused  even  with  low  doses  of  aspirin.  Cap-
ule  endoscopy  and  enteroscopy  also  showed  the  presence
f  erosions,  ulcers,  and  strictures  in  chronic  NSAID  users.54
15.-  NSAID  and  ASA  use  can  be  associated  with
omplications  of  diverticular  disease  of  the  colon.
Agreement  reached:  75%  in  total  agreement,  20%  in  par-
ial  agreement,  5%  uncertain.
Evidence,  albeit  scarce,  suggests  an  increased  risk  for
eveloping  complications  related  to  diverticular  disease  of
he  colon.  In  a  systematic  review  by  Laine  et  al.,55 in
hich  7  studies  with  different  methodologies  were  ana-
yzed,  5  of  them  showed  a  significant  increase  in  the  risk
or  complication  of  diverticular  disease  in  chronic  NSAID
sers.  In  an  observational  case-control  study,  Taki  et  al.56
eported  that  bilateral  diverticular  disease  (OR  =  3.00),  nsN-
AID  use  (OR  =  3.47),  low  doses  of  aspirin  (OR  =  2.23),  and
nticoagulants  (OR  =  3.09)  were  independent  risk  factors  for
iverticular  bleeding.
16.-  The  effect  of  NSAID  intake  on  inflammatory  bowel
isease  is  still  uncertain.
Agreement  reached:  100%  in  total  agreement.
Some  studies  have  pointed  out  that  nsNSAID  and  selective
OX-2  inhibitor  use  can  be  a  risk  factor  for  the  exacerbation
f  inflammatory  bowel  disease,  specifically  in  Crohn’s  dis-
ase  and  ulcerative  colitis,57,58 but  other  studies  have  not
ound  such  an  association.59,60 Recently,  in  the  systematic
eview  and  meta-analysis  by  Moninuola  et  al.,61 evaluat-
ng  the  risk  for  inflammatory  bowel  disease  exacerbation
ith  the  use  of  acetaminophen  and  NSAIDs,  no  consistent
ssociation  was  found  between  the  use  of  acetaminophen,
sNSAIDs,  or  selective  COX-2  inhibitors  and  disease  exacer-
ation.
17.-  Capsule  endoscopy  and  enteroscopy  are  diag-
ostic  methods  that  directly  evaluate  NSAID-induced
nteropathy.
Agreement  reached:  90%  in  total  agreement,  5%  uncer-
ain,  5  in  partial  disagreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of.
Since  capsule  endoscopy  and  enteroscopy  have  become
vailable  for  the  direct  evaluation  of  the  small  bowel,  the
etection  of  lesions  in  that  segment  of  the  digestive  system
as  been  on  the  rise.62,63 It  is  known  that  50-70%  of  patients
hat  are  long-term  NSAID  users  will  develop  damage  in  the
mall  bowel.51
Currently,  both  diagnostic  methods  are  available,  and
ven  though  the  capacity  to  detect  small  bowel  lesions  is
ot  perfect,  enteroscopy  is  superior  to  capsule  endoscopy
n  detecting  large  lesions,  such  as  polyps,  whereas  cap-
ule  endoscopy  is  superior  in  detecting  small  lesions,  such
s  erosions  and  red  spots.62 Although  there  is  no  validated
erminology  for  reporting  the  findings  of  NSAID-induced
nteropathy,  Hayashi  et  al.64 propose  the  following  criteria
or  diagnosing  NSAID-induced  enteropathy  through  double
alloon  enteroscopy: A  history  of  NSAID  use.
 Endoscopic  findings:  erosion,  ulcer,  and  diaphragm-like
stricture.
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-  Improvement  of  clinical  findings  (signs  and  symptoms)
or  endoscopic  findings  upon  NSAID  suspension,  with  the
exception  of  diaphragm-like  stricture.
-  Exclusion  of  other  causes  (tumor,  inflammatory  bowel  dis-
ease,  infectious  disease).
In  addition,  Maiden  et  al.65 classified  endoscopic  find-
ings  of  NSAID-induced  enteropathy  into  5  categories  (Fig.  1),
utilizing  capsule  endoscopy:
-  Erythematous  folds.
-  Areas  of  denuded  mucosa.
-  Red  spots.
- Disruption  of  the  mucosa.
-  Bleeding.
Enteroscopy  provides  direct  viewing  and  better  lesion
characterization.  In  addition,  biopsies  can  be  taken  for  addi-
tional  histopathologic  study.42 Unlike  capsule  endoscopy,
it  also  has  therapeutic  advantages,  given  that  endoscopic
dilations  can  be  performed  in  cases  of  diaphragm-like
strictures.66
18.-  The  performance  of  gastroduodenoscopy,
colonoscopy,  or  both  studies,  is  justified  in  NSAID  users,
in  the  presence  of  risk  factors  or  alarm  symptoms.
Agreement  reached:  75%  in  total  agreement,  25%  in  par-
tial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
A1,  strong,  in  favor  of.
The  presence  of  symptoms  is  common  in  NSAID  users  and
their  onset  appears  to  vary,  depending  on  the  NSAID  utilized,
as  described  in  statement  13.  Even  though  around  1-2%  of
NSAID  users  will  develop  a  serious  complication  during  treat-
ment,  it  is  very  important  to  underline  that  up  to  50%  of  the
patients  that  present  with  a  severe  complication  reported  no
previous  symptoms.  Therefore,  preventive  measures  should
be  implemented,  based  on  the  presence  of  risk  factors.24
Endoscopy  is  basically  used  in  clinical  evaluations  to
determine  acute  or  chronic  damage  caused  by  NSAID  tox-
icity  in  the  digestive  tract.  However,  none  of  the  present
consensuses  or  guidelines  recommends  its  routine  use.  The
management  of  patients  that  are  going  to  receive  treatment
with  NSAIDs  must  always  be  preceded  by  the  correct  evalu-
ation  of  the  individual  gastrointestinal  risks  of  each  patient.
For  example,  the  Mexican  consensus  on  dyspepsia
suggests  performing  endoscopy  on  all  patients  with  unin-
vestigated  dyspepsia  that  present  with  alarm  symptoms
or  initial  treatment  failure  directed  at  the  predomi-
nant  symptom.67 In  addition,  the  American  Society  for
Gastrointestinal  Endoscopy  (ASGE)  states  that  endoscopic
examination  is  justified  when  there  are  alarm  symptoms
(symptoms  of  dyspepsia  in  patients  above  50  years  of  age,
weight  loss,  gastrointestinal  bleeding,  iron  deficiency  ane-
mia,  obstructive  symptoms,  a  family  history  of  cancer,  or
imaging  studies  suggestive  of  organic  disease).68 Table  2
shows  the  main  risk  factors  that  justify  the  performance
of  endoscopic  studies  in  the  context  of  NSAID-induced
enteropathy.Table  3  shows  the  stratification  of  patients  into  3  dif-
ferent  groups,  based  on  the  presence  or  absence  of  risk
factors.47 For  example,  in  a  study  conducted  by  the  National
Health  System  in  Spain,  there  was  a  mortality  rate  of  15.3
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or  every  100,000  NSAID-ASA  users.  Approximately  50%  of
he  patients  in  that  study  that  died  had  one  or  more  of  the
ollowing  risk  factors:  peptic  ulcer  (22.6%),  gastrointestinal
leeding  (15.3%),  dyspepsia  (13.3%),  heart  disease  (65.1%),
nd  high  blood  pressure  (40%).30
Importantly,  not  all  patients  with  acute  or  chronic  NSAID
se  require  gastroprotection.  Therefore,  it  is  necessary  to
valuate  each  patient  individually  and  make  the  correspond-
ng  decision  based  on  that  risk.30
19-  Capsule  endoscopy  in  NSAID  users  is  used  for
he  evaluation  of  patients  with  anemia  or  gastrointesti-
al  bleeding,  when  esophagogastroduodenoscopy  and
olonoscopy  have  not  identified  the  cause.
Agreement  reached:  80%  in  total  agreement,  20%  in  par-
ial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
2,  weak,  in  favor  of.
Five  to  ten  percent  of  all  gastrointestinal  bleeding  orig-
nates  in  the  small  bowel.69,70 With  the  advent  of  capsule
ndoscopy  (2001)  and  enteroscopy  (2004),  it  is  now  possible
o  detect  up  to  75%  of  the  causes  of  bleeding  that  arise  in  the
mall  bowel.71 The  current  guidelines  of  the  American  Col-
ege  of  Gastroenterology  suggest  performing  a  second  look,
tilizing  gastroduodenoscopy  and  colonoscopy  in  patients
ith  recurrent  hematemesis,  melena,  a  previously  incom-
lete  endoscopic  examination,  recurrent  hematochezia,  or
uspicion  of  distal  origin.  If  the  origin  of  the  bleeding  is  not
ound,  small  bowel  bleeding  should  be  considered.  There-
ore,  the  performance  of  capsule  endoscopy  as  a  first  option
or  evaluating  those  patients  is  recommended.72
20.-  Enteroscopy  in  NSAID  users  is  indicated  for  small
owel  evaluation,  biopsy,  and  lesion  dilation.
Agreement  reached:  100%  in  total  agreement.
Quality  of  evidence  and  strength  of  recommendation:
2,  weak,  in  favor  of.
In  addition  to  offering  the  possibility  to  directly  observe
he  mucosal  surface,  characterize  findings,  and  take  biop-
ies,  enteroscopy  can  be  therapeutic.  For  example,  it
rovides  the  option  of  hemostatic  treatment  and  the  perfor-
ance  of  dilations,  specifically  when  there  is  diaphragm-like
tricture  (concentric  projections  of  submucosal  fibrosis  that
an  cause  nonspecific  or  obstructive  symptoms),  which  is
n  uncommon  but  pathognomonic  finding  of  NSAID-induced
nteropathy.63,64 The  therapeutic  success  of  the  endoscopic
ilation  of  those  lesions,  when  indicated,  is  80%.73 A  system-
tic  review  on  endoscopic  dilation  of  small  bowel  stricture
howed  that  said  intervention  makes  surgery  unnecessary  in
 out  of  every  5  patients,  with  a  complication  rate  of  4.8%
er  patient  and  2.6%  per  dilation.74
21.-  Intestinal  damage  biomarkers  can  be  useful  in
valuating  NSAID-induced  enteropathy.
Agreement  reached:  80%  in  total  agreement,  20%  in  par-
ial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of.
As  described  in  statement  2,  both  the  increase  in  perme-
bility  and  inflammation  of  the  mucosa  are  pathophysiologic
echanisms  associated  with  NSAID  use.  In  that  sense,
iomarkers  that  indirectly  evaluate  intestinal  permeabil-
ty,  such  as  calprotectin,  fecal  lactoferrin,  the  urinary
xcretion  of  chromium-51  EDTA  (51Cr-EDTA),  Indium-111
In-111)-labeled  leukocyte  scintigraphy,  and  radiolabeled
198
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Table  3  Risk  categories  for  the  development  of  NSAID-induced  gastroduodenopathy.
Risk  Events  for  every
100  patients  per
year
Low  No  risk  factors  and  no  low-dose
ASA  intake
<  1.5
Moderate No  history  of  peptic  ulcer,  no
anticoagulation  +  1-2  risk
factors
1.5  a  10
High A  history  of  peptic  ulcer,
anticoagulants  or  >  2  risk
factors
>  10
Source: Adapted from Lanas et al.47.
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Figure  1  A  52-year-old  man  with  chronic  diclofenac  use.  A-B)  Capsule  endoscopy  image  in  which  active  bleeding  in  the  jejunum
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Original images:  Dr.  Jose  María  Remes  Troche.
erythrocyte  scintigraphy  can  potentially  be  applicable  in
clinical  practice.23 The  tests  for  measuring  intestinal  per-
meability  are  based  on  the  detection  of  orally  administered
compounds  that  are  eliminated  by  urine.  Under  normal
conditions,  those  compounds  should  be  incapable  of  being
absorbed,  but  when  there  is  damage  to  the  barrier  or  intesti-
nal  damage,  they  enter  the  circulatory  system,  to  then  be
eliminated.75 The  51Cr-EDTA  test  is  one  of  the  most  widely
employed,  through  which  50-70%  of  long-term  NSAID  users
have  been  reported  to  develop  an  increase  in  intestinal
permeability.76 Many  of  those  tests  are  promising  but  more
studies  are  needed  to  determine  the  role  of  each  one.77
Prevention  and  treatment
22.-  NSAID  prescription  should  always  be  preceded  by  an
integral  evaluation  of  the  gastrointestinal  and  cardiovas-
cular  risks.
Agreement  reached:  100%  in  total  agreement.
Quality  of  evidence  and  strength  of  recommendation:
A1,  strong,  in  favor  of.
Before  beginning  therapy  with  an  NSAID,  the  real
necessity  of  it  should  be  carefully  evaluated  and  the  car-
diovascular  and  gastrointestinal  risks  calculated  for  each
individual.  Risk  factors  are  those  established  in  statement
u
2
o
ted  ulcers  is  then  viewed.
8  and  Table  1.  Likewise,  as  described  in  statement  18
Table  2),  with  the  presence  or  absence  of  those  factors,
 different  risk  groups  are  established.  The  gastrointestinal
revention  strategy  to  be  adopted  will  depend  on  the  group
n  which  the  patient  is  included.
23.-  NSAID  prescription  should  be  avoided,  or  pre-
cribed  together  with  a  PPI,  in  subjects  that  have
astrointestinal  risk  factors.
Agreement  reached:  80%  in  total  agreement,  20%  in  par-
ial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of.
If  NSAID  use  cannot  be  avoided,  there  is  evidence
ecommending  its  concomitant  prescription  with  PPIs  for
rophylactic  purposes.  For  example,  the  results  of  2
dentical,  randomized  placebo-controlled  clinical  trials  by
cheiman  et  al.,78 the  VENUS  study  (the  United  States,
 =  844)  and  the  PLUTO  study  (international,  n  =  585),  were
ublished.  Both  trials  included  high-risk  patients  with  no
ctive  ulcer  (≥  65  years  of  age  or  a  history  of  pep-
ic  ulcer  disease  within  the  last  5  years)  that  continued
nder  chronic  treatment  with  nsNSAIDs  or  selective  COX-
 inhibitors.  Esomeprazole  (20  mg  or  40  mg  administered
nce  a day)  was  compared  with  placebo,  with  respect  to
he  rate  of  ulcer  development  at  6  months.  The  remis-
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ion  rates  at  the  end  of  the  study  period  were  79.6%
or  placebo,  94.7%  for  esomeprazole  20  mg/day,  and  95.3%
or  esomeprazole  40  mg/day  (p  =  0.001  for  both,  com-
ared  with  placebo)  in  the  VENUS  study  and  87.7%  for
lacebo,  94.8%  for  esomeprazole  20  mg/day  (p  =  0.018),  and
5.6%  for  esomeprazole  40  mg/day  (p  =  0.007)  in  the  PLUTO
tudy.  In  the  grouped  analysis  that  included  only  COX-2
nhibitors,  the  remission  rates  were  83.5%  with  placebo,
9.1%  with  esomeprazole  20  mg/day  (p  =  0.001),  and  95.9%
ith  esomeprazole  40  mg/day  (p  =  0.002).  Both  trials  showed
he  effectiveness  of  a  PPI  in  the  prevention  of  gastroin-
estinal  damage  in  long-term  nsNSAID  and  selective  COX-2
nhibitor  users  in  a  high-risk  population.
24.-  Prescribing  the  minimum  dose  of  an  NSAID  for  the
hortest  period  of  time  possible  to  achieve  the  desired
ffect  is  associated  with  a  lower  risk  for  gastrointestinal
dverse  effects.
Agreement  reached:  90%  in  total  agreement,  10%  in  par-
ial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of.
The  decision  to  prescribe  an  nsNSAID  or  selective  COX-2
nhibitor  should  be  balanced  and  influenced  by  possible  car-
iovascular  and  gastrointestinal  events.  Nevertheless,  the
omparative  anti-inflammatory  and  analgesic  efficacy  is  also
mportant.  The  comparative  effectiveness  has  been  shown
n  several  controlled  clinical  trials  (CCTs).  For  example,
ne  CCT  reported  that  the  efficacy  of  etoricoxib  was  sim-
lar  to  that  of  diclofenac  in  patients  with  osteoarthritis.79
nother  CCT  showed  similar  efficacy  between  celecoxib  and
aproxen.80 In  the  CONDOR  study,  analyzing  celecoxib  versus
meprazole  and  diclofenac  in  patients  with  osteoarthritis
nd  rheumatoid  arthritis,  there  was  no  difference  in  effec-
iveness  between  celecoxib  and  diclofenac  in  patients  with
steoarthritis.81 A  meta-analysis  of  CCTs  in  patients  with
heumatologic  diseases  showed  no  increased  cardiovascu-
ar  risk  associated  with  celecoxib,  compared  with  placebo,82
hereas  a  safety  analysis  of  6  CCTs  conducted  on  patients
ith  diseases  different  from  arthritis  provided  evidence  of
 cardiovascular  risk  that  was  dependent  on  the  dose  of
elecoxib,  the  regimen,  and  the  initial  cardiovascular  risk.83
he  risk  did  not  appear  to  be  significant  (RR  =  1.1)  for  the
00  mg/day  dose,  it  was  intermediate  for  the  200  mg/day
ose  twice  a  day  (RR  =  1.8),  and  high  for  the  400  mg/day
ose  twice  a  day  (RR  =  3.1).84 In  a  meta-analysis  on  selective
OX-2  inhibitors  and  nsNSAIDs,  there  was  a  trend  towards  a
ower  risk  with  lower  doses  of  celecoxib.84
However,  the  cost  of  treatment  is  also  an  important  fac-
or.  After  the  results  of  the  CONDOR  study  were  published,
he  economic  model  from  the  clinical  guidelines  of  the
ational  Institute  for  Care  Excellence  (NICE)  of  the  United
ingdom  was  updated  in  2012  to  include  the  relative  risks  of
dverse  events  related  to  the  lower  digestive  tract.85
25.-  PPIs  are  safe  and  efficacious  drugs  in  the  pre-
ention  of  gastroduodenal  complications  associated  with
hronic  NSAID  use.
Agreement  reached:  90%  in  total  agreement,  10%  in  par-
ial  agreement.Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of.
PPIs,  such  as  omeprazole,  pantoprazole,  lansoprazole,
someprazole,  dexlansoprazole,  etc.,  are  effective  and
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ell-tolerated  drugs  that  act  by  inhibiting  gastric  H/K-
denosine  triphosphatase  by  covalent  bonding  to  the
ysteines  of  the  proton  pump,  thus  reducing  gastric  acid
ecretion.  In  a  systematic  review  with  a  meta-analysis  of
1  clinical  trials  that  included  12,532  participants,  con-
ucted  to  evaluate  PPI  safety  and  efficacy,  PPIs  were
ignificantly  more  effective  than  placebo  in  reducing  the
omplications  from  ulcers  (RR  =  0.29)  and  endoscopic  peptic
lcers  (RR  =  0.27).86 When  a  subgroup  analysis  was  carried
ut,  there  were  no  differences  according  to  the  class  of
SAID,  risk  for  ulcer,  history  of  ulcer  disease,  H.  pylori  infec-
ion,  or  age.  The  number  needed  to  treat  and  prevent  a
omplication  of  ulcer,  was  10  high-risk  patients  and  268
oderate-risk  patients.86 A  network  meta-analysis  indicated
hat  the  effectiveness  of  the  different  PPIs  in  reducing  the
omplications  of  ulcers  and  endoscopic  peptic  ulcers  was
imilar.  PPIs  significantly  reduced  the  adverse  gastrointesti-
al  events  and  related  treatment  withdrawals,  compared
ith  placebo.  There  were  no  differences  in  safety  among
he  different  PPIs.86
26.-  PPIs  at  standard  doses  are  more  recommendable
han  H2  receptor  antagonists  (H2RAs)  and  misoprostol  for
educing  the  risk  for  peptic  ulcer  and  its  complications  in
atients  with  long-term  NSAID  use.
Agreement  reached:  75%  in  total  agreement,  25%  in  par-
ial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of.
PPIs  have  become  the  cornerstone  for  gastroprotection,
ompared  with  other  therapies  that  inhibit  gastric  acid
ecretion.  For  example,  a  pivot  study  compared  omeprazole
0  mg/day  with  ranitidine  150  mg  twice  a  day  for  12  weeks,
n  425  NSAID-using  patients,  as  prophylaxis  for  gastric  ulcer
nd  duodenal  ulcer.  Omeprazole  was  superior  to  ranitidine  in
reventing  both  gastric  ulcer  (RR  =  0.32)  and  duodenal  ulcer
RR  =  0.11).87 Four  studies  that  included  a  total  of  1,478
atients  compared  a  PPI  with  misoprostol  400-800  g)  per
ay  and  found  that  PPIs  were  superior  to  misoprostol  for
he  prevention  of  duodenal  ulcer  (RR  =  0.25),  but  not  of  gas-
ric  ulcer  (RR  =  1.61,  random  effects)  or  the  total  of  ulcers
RR  =  0.90).88--91
Two  trials  that  included  600  patients  compared  misopros-
ol  (400  to  800  g)  with  150  mg  of  ranitidine  twice  a  day.92,93
isoprostol  was  superior  to  standard-dose  ranitidine  for  the
revention  of  gastric  ulcers  induced  by  traditional  NSAIDs
RR  =  0.12)  but  not  for  duodenal  ulcers  (RR  =  1.00).  In  a  meta-
nalysis  of  patients  that  received  misoprostol  plus  an  NSAID
ersus  placebo,  the  incidence  of  gastric  ulcers  decreased  by
4%  and  duodenal  ulcers  by  58%.94 The  main  limiting  factor
mpeding  the  generalized  use  of  misoprostol  as  a  protec-
ive  agent  is  the  elevated  frequency  of  side  effects,  such  as
iarrhea,  abdominal  cramps,  and  nausea  in  up  to  20%  of  its
sers,  which  limits  patient  compliance.
27.-  In  patients  receiving  NSAID  therapy  with  no
ntiplatelet  drugs,  PPI  prescription  is  recommended  only
hen  there  is  a  risk  for  gastrointestinal  complications.
Agreement  reached:  80%  in  total  agreement,  15%  in  par-
ial  agreement,  5%  uncertain.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of.
To  evaluate  the  comparative  effectiveness  of  the  dif-
erent  clinical  strategies  for  preventing  NSAID-induced
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gastrointestinal  toxicity,  Chinese  researchers  conducted  a
pairwise  and  Bayesian  network  meta-analysis  that  included
82  CCTs.  They  compared  the  risk  for  gastrointestinal
adverse  events  in  nsNSAID  or  selective  COX-2  inhibitor
users  that  received  gastroprotection  with  a  PPI,  H2RA,  or
misoprostol.95 For  all  of  the  efficacy  evaluation  criteria,  the
concomitant  prescription  of  a  selective  COX-2  inhibitor  +  PPI
was  associated  with  the  least  absolute  probability  of  an
adverse  event  and  the  highest  safety  range,  followed  by
selective  COX-2  inhibitors  alone,  and  in  third  place,  nsN-
SAIDs  plus  PPIs.95
28.-  In  patients  at  high  risk  for  a  gastroduodenal  event
and  low  risk  for  a  cardiovascular  event,  the  best  strategy
for  preventing  NSAID-associated  damage  is  the  combina-
tion  of  a  selective  COX-2  inhibitor  and  PPI.
Agreement  reached:  100%  in  total  agreement.
Quality  of  evidence  and  strength  of  recommendation:
C1,  strong,  in  favor  of.
As  described  in  statements  8  and  9,  the  safety  profile  of
selective  COX-2  inhibitors  is  superior  to  that  of  nsNSAIDs,
in  relation  to  gastrointestinal  risk.  The  CONDOR  study,81
and  the  more  recent  GI-REASONS  study,96 showed  that
celecoxib  exhibited  greater  safety  in  the  entire  gastroin-
testinal  tract,  compared  with  diclofenac  plus  omeprazole.
A  recent  meta-analysis  that  included  52  randomized  clini-
cal  trials  demonstrated  that  celecoxib  was  associated  with
a  significantly  lower  risk  for  all  clinically  significant  gastroin-
testinal  events  in  the  entire  digestive  tract,  compared  with
nsNSAIDs.97
29.-  In  patients  at  high  risk  for  cardiovascular  and  gas-
troduodenal  events,  the  combination  of  naproxen  and  a
proton  pump  inhibitor  is  recommended.
Agreement  reached:  85%  in  total  agreement,  15%  in  par-
tial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
B1,  strong,  in  favor  of.
The  most  recent  and  extensive  meta-analysis  of  clinical
trials  with  individual  patient  data  points  out  that  both  selec-
tive  COX-2  inhibitors  and  nsNSAIDs  increase  cardiovascular
risk,  compared  with  placebo,  with  no  significant  overall  dif-
ferences  between  them.  Of  the  nsNSAIDs,  diclofenac  was
the  one  with  greater  cardiovascular  risk,  and  it  was  similar
to  that  of  the  selective  COX-2  inhibitors.  Naproxen,  at  a  dose
of  500  mg  every  12  h,  was  not  associated  with  an  increased
cardiovascular  risk,  unlike  ibuprofen  and  diclofenac,  the
most  widely  studied  nsNSAIDs.95 A  particular  case  is  that  of
patients  that  take  ASA.  It  must  be  kept  in  mind  that  NSAIDs,
such  as  naproxen,  and  especially  ibuprofen,  interfere  with
the  antiplatelet  activity  of  ASA.98 Given  naproxen’s  good
cardiovascular  safety  profile,  its  administration  2  h  after  ASA
intake  should  minimize  that  risk,  making  it  a  good  option  in
those  patients.20
30.-  PPIs  are  not  useful  for  preventing  NSAID-induced
enteropathy  and  can  even  be  harmful.
Agreement  reached:  85%  in  total  agreement,  10%  in  par-
tial  agreement.  5%  in  partial  disagreement.
Quality  of  evidence  and  strength  of  recommendation:
C2,  weak,  against  the  intervention.In  contrast  to  the  stomach  and  duodenum,  there  is
no  evidence  that  gastric  acid  plays  a  role  in  the  patho-
genesis  of  NSAID-induced  gastrointestinal  damage  distal  to
the  ligament  of  Treitz.33 Chronic  suppression  of  gastric
a
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cid  secretion  (with  PPIs  or  H2RAs)  causes  small  intesti-
al  bacterial  overgrowth,  which  can  increase  the  severity
f  NSAID-induced  enteropathy.  Studies  on  rodents  suggest
hat  PPIs  actually  exacerbate  NSAID-induced  enteropathy,
nstead  of  providing  a  beneficial  effect.99 In  that  study,  the
ats  treated  with  a  PPI  (omeprazole  or  lansoprazole)  devel-
ped  substantially  more  ulcers  and  intestinal  bleeding  when
imultaneously  treated  with  an  NSAID  (naproxen  or  cele-
oxib)  than  the  group  treated  with  placebo  plus  the  NSAID.
 series  of  studies  with  capsule  endoscopy  showed  a  high
ncidence  (55-75%)  of  damage  in  the  small  bowel  in  healthy
olunteers  that  took  an  NSAID  plus  a PPI  for  2  weeks.51,100--102
mportantly,  that  high  incidence  of  intestinal  damage  was
bserved  in  a  group  considered  to  be  at  low  risk  for  NSAID-
nduced  gastrointestinal  damage  that  underwent  short-term
reatment  with  the  co-administration  of  a  gastroprotective
edication  (PPI).  In  a  cross-sectional  study  utilizing  capsule
ndoscopy  performed  on  patients  with  rheumatoid  arthritis,
reated  with  an  NSAID  for  more  than  3  months,  the  advanced
ge  patients  and  acid  suppression  users  (H2RAs  and  PPIs)  had
ore  probability  of  developing  severe  enteropathy.50
31.-  Before  beginning  long-term  treatment  with  an
SAID,  Helicobacter  pylori  infection  should  be  evaluated
nd  treated.
Agreement  reached:  90%  in  total  agreement,  10%  in  par-
ial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of  the  intervention.
The  detection  of  H.  pylori  infection  for  the  prevention  of
lcers  in  asymptomatic  patients  should  be  evaluated  indi-
idually  and  its  routine  performance  is  not  recommended.
evertheless,  the  study  and  eradication  of  H.  pylori  is  rec-
mmended  in  patients  with  a  history  of  peptic  ulcer  disease,
efore  beginning  treatment  with  low  doses  of  aspirin  or  an
SAID.39 H.  pylori  infection  is  an  independent  risk  factor
or  developing  ulcers  and  bleeding  due  to  ulcers  in  NSAID
sers.103,104 Eradicating  H.  pylori  infection  before  beginning
reatment  with  NSAIDs  reduces  the  risk  for  developing  pep-
ic  ulcers  and  bleeding  due  to  ulcers.105,106 A  meta-analysis
f  5  CCTs  suggested  that  the  eradication  of  H.  pylori  infec-
ion  in  patients  that  take  NSAIDs  was  associated  with  a  57%
ecrease  in  the  incidence  of  peptic  ulcer  (OR  =  0.43;  95%  CI:
.20-0.93).28 With  respect  to  chronic  NSAID  users,  the  evi-
ence  suggests  that  H.  pylori  eradication  per  se  does  not
educe  the  incidence  of  peptic  ulcers  and  that  therapy  with
 PPI  is  a  strategy  that  provides  a  more  efficacious  effect  on
educing  the  risk  for  ulcer  than  H.  pylori  eradication.107,108
32.-  There  are  other  alternatives  for  the  prophylaxis
nd  treatment  of  NSAID-induced  gastroduodenopathy  and
nteropathy  that  have  limited  usefulness  and  availability.
Agreement  reached:  85%  in  total  agreement,  15%  in  par-
ial  agreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of  the  intervention.
Misoprostol,  metronidazole,  and  sulfasalazine  have  been
uggested  to  be  beneficial  in  the  treatment  or  preven-
ion  of  NSAID-induced  enteropathy  in  humans.  Nevertheless,
he  majority  of  studies  have  significant  limitations,  such
s  being  open,  non-controlled  studies,  with  small  sample
izes.  The  observations  in  animal  studies  that  NSAID-induced
nteropathy  was  accompanied  with  dramatic  changes  in  the
umber  and  type  of  gut  bacteria  led  to  a  series  of  stud-
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es  on  the  potential  value  of  probiotics  for  the  treatment
r  prevention  of  NSAID-induced  enteropathy.  The  Shirota
train  of  Lactobacillus  casei  has  been  reported  to  protect
gainst  small  bowel  lesions  induced  by  indomethacin  in  rats
nd  that  its  probiotic  effects  might  be  mediated  by  the
nti-inflammatory  effects  of  lactic  acid,  but  those  findings
ave  not  been  shown  in  humans.109 More  recently,  other
uthors  demonstrated  that  the  treatment  with  a  mixture
f  probiotics  (VSL  #3)  that  contains  L.  casei  significantly
educed  fecal  calprotectin  concentrations  in  healthy  vol-
nteers  that  received  indomethacin.110 Rebamipide  is  an
nti-ulcer  cytoprotecting  agent  that  stimulates  endogenous
rostaglandin  production  and  has  been  utilized  in  sev-
ral  Asian  countries  for  the  treatment  of  gastric  ulcers
nd  gastric  lesions,  such  as  erosions  and  edema  associ-
ted  with  acute  gastritis.111--113 There  is  good  evidence  that
ebamipide  increases  endogenous  levels  of  prostaglandins,
ncreases  blood  flow,  suppresses  the  increases  in  permeabil-
ty,  eliminates  free  radicals,  and  suppresses  inflammation  in
he  gastric  mucosa.114--116 Through  those  actions,  rebamipide
as  also  been  shown  to  be  useful  in  the  prevention  of  aspirin-
nduced  gastrointestinal  lesions.  It  has  even  been  described
o  have  a  preventive  effect  on  small  bowel  erosions  of  the
ucosa  in  the  ileum  induced  by  aspirin,  compared  with
lacebo.117 In  a  randomized  controlled  trial  conducted  on
atients  receiving  low  doses  of  aspirin  or  an  NSAID  for  more
han  3  months,  rebamipide  was  efficacious  in  the  cure  of
rosions  and  ulcers  of  the  small  bowel.118
33.-  There  is  currently  no  useful  treatment  for  NSAID-
nduced  enteropathy  and  the  recommendation  is  to
uspend  the  drug,  if  possible.
Agreement  reached:  100%  in  total  agreement.
Quality  of  evidence  and  strength  of  recommendation:
1,  strong,  in  favor  of  the  intervention.
At  present  there  are  no  therapies  that  have  proven  to
e  efficacious  in  treating  NSAID-induced  enteropathy,  and
etection  of  the  disease  continues  to  be  a  challenge,  espe-
ially  due  to  the  scant  correlation  between  tissue  lesion  and
ymptoms.  In  addition,  recent  studies  indicate  that  drugs
ommonly  used  to  protect  the  upper  gastrointestinal  tract
i.e.,  PPIs)  can  significantly  worsen  NSAID-induced  damage
n  the  small  bowel.  The  evaluation  of  risk  for  enteropathy
as  been  hindered  by  the  lack  of  knowledge  about  its  corre-
ponding  risk  factors,  unlike  those  related  to  complications
f  the  upper  gastrointestinal  tract.  The  data  analysis  of  the
EDAL  program  (i.e.,  the  MEDAL,  EDGE-I,  and  EDGE-II  stud-
es)  showed  that  the  risk  for  a  clinical  event  in  the  lower
igestive  tract  from  NSAID  use  appears  to  be  constant  over
ime  and  the  main  risk  factors  are  a  previous  lower  gastroin-
estinal  event  and  advanced  age.119 In  a  post  hoc  analysis  of
he  CONDOR  trial,81 baseline  levels  of  C-reactive  protein,  a
istory  of  gastritis  and  gastrointestinal  intolerance,  H.  pylori
nfection,  advanced  age,  and  body  mass  index  were  associ-
ted  with  clinically  significant  blood  loss  in  patients  with
steoarthritis  that  were  treated  with  NSAIDs.
onclusionst  is  essential  for  all  prescribing  physicians  to  carry  out  an
ndividualized  evaluation  of  the  cardiovascular  and  gastroin-
estinal  risk  profile  of  each  patient  receiving  treatment  with
i
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SAIDs.  Once  the  risk  profile  is  determined,  the  most  ade-
uate  therapeutic  option  for  each  case  must  be  searched
or.  Treatment  with  NSAIDs  should  be  avoided  in  high-risk
atients  (those  with  a history  of  complicated  peptic  ulcer  or
nti-thrombotic  therapy).  H.  pylori  should  be  eradicated  in
nfected  patients  with  a  history  of  ulcer,  and  selective  COX-2
nhibitors  plus  PPIs  prescribed.  Naproxen  is  the  ideal  NSAID
or  patients  with  a  high  cardiovascular  risk,  with  the  addition
f  PPIs  if  there  is  associated  gastrointestinal  risk.  Regarding
SAID-induced  enteropathy,  it  is  increasingly  more  frequent,
nd  although  there  is  greater  diagnostic  capacity,  prophy-
axis  and  treatment  are  still  limited.
inancial disclosure
he  present  consensus  was  carried  out  with  the  support
f  the  Asociación  Mexicana  de  Gastroenterología, which
nabled  the  participation,  transportation,  and  lodging  dur-
ng  the  face-to-face  voting.  No  professional  fees  were
eceived.
onflicts of  interest
r.  María  Victoria  Bielsa-Fernández  declares  she  has  no  con-
ict  of  interest.
Dr.  José  Luis  Tamayo  de  la  Cuesta  has  been  a  speaker  for
nd  advisory  board  member  of  Takeda  and  Chinoin.
Dr.  Jesús  Lizárraga  López  declares  he  has  no  conflict  of
nterest.
Dr.  José  María  Remes-Troche  is  an  advisory  board  mem-
er  of  Takeda  and  Asofarma.  He  has  received  research  funds
rom  Sanfer  and  Asofarma.  He  is  a  speaker  for  Takeda,
sofarma,  Alfa-Wassermann,  Carnot,  Menarini,  and  Astra-
eneca.
Dr.  Ramón  Isaías  Carmona-Sánchez  is  or  has  been  a
peaker  for  Asofarma,  Astra-Zeneca,  and  Chinoin.
Dr.  Juan  Manuel  Aldana  Ledesma  declares  he  has  no  con-
ict  of  interest.
Dr.  José  Manuel  Avendan˜o  Reyes  declares  he  has  no  con-
ict  of  interest.
Dr.  Mario  Arturo  Ballesteros  Amozorrutia  declares  he  has
o  conflict  of  interest.
Dr.  Mauricio  De  Arin˜o  declares  he  has  no  conflict  of  inter-
st.
Dr.  Louis  de  Giau  Troulitz  declares  he  has  no  conflict  of
nterest.
Dr.  Ricardo  Flores  Rendón  has  been  a  speaker  for  Takeda.
Dr.  Héctor  Huerta  Guerrero  declares  he  has  no  conflict  of
nterest.
Dr.  José  Alberto  González  declares  he  has  no  conflict  of
nterest.
Dr.  Angélica  Hernández  Guerrero  declares  she  has  no  con-
ict  of  interest.
Dr.  Enrique  Murcio  Pérez  declares  he  has  no  conflict  of
nterest.
Dr.  Joel  Jacquez  Quintana  declares  he  has  no  conflict  of
nterest.
Dr.  Arturo  Meixueiro  Daza  declares  he  has  no  conflict  of
nterest.
Dr.  José  Ramón  Nogueira  de  Rojas  declares  he  has  no
onflict  of  interest.
vent
,The  Mexican  consensus  on  the  diagnosis,  treatment,  and  pre
Dr.  Heriberto  Rodríguez  Hernández  declares  he  has  no
conflict  of  interest.
Dr.  Ricardo  Santoyo  Valenzuela  declares  he  has  no  conflict
of  interest.
Dr.  Sandra  Concepción  Solorzano  Olmos  declares  she  has
no  conflict  of  interest.
Dr.  Luis  F.  Uscanga  Domínguez  is  an  advisory  board  mem-
ber  of  Asofarma.
Dr.  Felipe  Zamarripa  Dorsey  declares  he  has  no  conflict
of  interest.
References
1. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced
gastrointestinal complications. J Rheumatol. 1999;56:18--24.
2. Scottish Intercollegiate Guidelines Network (SIGN).
http://www.sign.ac.uk/methodology/checklists.html.
3. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging
consensus on rating quality of evidence and strength of rec-
ommendations. BMJ. 2008;336:924--6.
4. On˜ate-Ocan˜a LF, Ochoa-Carrillo FJ. El sistema GRADE para la
clasificar del nivel de evidencia y el grado de recomendaciones
en los informes de las guías clínicas. Cir Ciruj. 2009;77:417--9.
5. Medicines Uses and Spending in the U.S. A review of 2016
and Outlook to 2021. Report by the Quintiles IMS Insti-
tute. Estados Unidos: IQVIA Institute; 2017. Disponible en
https://www.iqvia.com/institute/reports/medicines-use-and-
spending-in-the-us-a-review-of-2016
6. Abraham NS, El-Serag HB, Johnson ML, et al. National
adherence to evidence-based guidelines for the prescrip-
tion of nonsteroidal antiinflammatory drugs. Gastroenterology.
2005;129:1171--8.
7. McGeer PL, Guo JP, Lee M, et al. Alzheimer’s Disease Can Be
Spared by Nonsteroidal Anti-Inflammatory Drugs. J Alzheimers
Dis. 2018;62:1219--22.
8. Flower RJ. The development of COX2 inhibitors. Nat Rev Drug
Discov. 2003;2:179--91.
9. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-
related injury to the gastrointestinal tract: clinical picture,
pathogenesis, and prevention. Gastroenterol Clin North Am.
2010;39:433--64.
10. Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of
damage to the gastrointestinal tract from nonsteroidal anti-
inflammatory drugs. Gastroenterology. 2018;154:500--14.
11. Sinha M, Gautam L, Shukla PK, et al. Current perspec-
tives in NSAID-induced gastropathy. Mediators Inflamm.
2013;2013:258209.
12. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects
of nonsteroidal anti-inflammatory drugs and cyclooxygenase-
2 selective agents on the small bowel: a cross-sectional
capsule enteroscopy study. Clin Gastroenterol Hepatol.
2007;5:1040--5.
13. Lim YJ, Yang CH. Non-steroidal anti-inflammatory drug-
induced enteropathy. Clin Endosc. 2012;45:138--44.
14. Sung JS, Noh CK, Lim SG, et al. Non-steroidal anti-
inflammatory drug-induced enteropathy. Intest Res.
2017;15:446--55.
15. Wallace JL. NSAID gastropathy and enteropathy: distinct
pathogenesis likely necessitates distinct prevention strategies.
Br J Pharmacol. 2012;165:67--74.
16. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA
2008 Expert consensus document on reducing the gastroin-
testinal risks of antiplatelet therapy and NSAID use: a report
of the American College of Cardiology Foundation Task Force
on Clinical Expert Consensus Documents. J Am Coll Cardiol.
2008;52:1502--17.ion  of  NSAID-induced  gastropathy  and  enteropathy  203
17. Musa D. Peptic ulcer disease and non-steroidal anti-
inflammatory drugs. Austr Prescr. 2017;40:91--3.
18. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects
of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and
coxibs) on upper gastrointestinal tract. Best Pract Res Clin
Gastroenterol. 2010;24:121--32.
19. Pérez-Aisa MA, Del Pino D, Siles M, et al. Clinical trends in ulcer
diagnosis in a population with high prevalence of Helicobacter
pylori infection. Aliment Pharmacol Ther. 2005;21:65--72.
20. Lanas A, Benito P, Alonso J, et al. Safe prescription recommen-
dations for non steroidal anti-inflammatory drugs: Consensus
document elaborated by nominated experts of three sci-
entific associations (SER-SEC-AEG). Gastroenterol Hepatol.
2014;37:107--27.
21. U.S. Food and Drug Administration, Disponible en: http:
//www.fda.gov/downloads/Drugs/DrugSafety/ucm089162.pdf
2007.
22. European Medicines Agency. European Medicines Agency
review concludes positive benefit-risk balance for non-
selective NSAIDs. London: EMA; 2006.
23. Wallace JL. Mechanisms, prevention and clinical implications
of nonsteroidal anti-inflammatory drug-enteropathy. World J
Gastroenterol. 2013;19:1861--76.
24. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal- anti-
nflammatory drugs and upper and lower gastrointestinal
mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3.
25. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory
drug (NSAID) enteropathy clinically more important than NSAID
gastropathy? Postgrad Med J. 2006;82:186--91.
26. Handa O, Naito Y, Fukui A, et al. The impact of non-steroidal
anti-inflammatory drugs on the small intestinal epithelium. J
Clin Biochem Nutr. 2014;54:2--6.
27. Lim YJ, Yang CH. Non-steroidal anti-inflammatory drug-
induced enteropathy. Clin Endosc. 2012;45:138--44.
28. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role
of Helicobacter pylori eradication in the prevention of peptic
ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411--8.
29. Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin
reuptake inhibitors and risk of upper gastrointestinal bleed-
ing: a systematic review and meta-analysis. Clin Gastroenterol
Hepatol. 2015;13:42--50.
30. Marcéna B, Sostres C, Lanas A. NSAID and gastrointestinal risk.
Aten Primaria. 2016;48:73--6.
31. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez
LA. Variability among nonsteroidal antiinflammatory drugs
in risk of upper gastrointestinal bleeding. Arthritis Rheum.
2010;62:1592--601.
32. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Phar-
macol. 2006;47:S60--66.
33. Hunt RH, Lanas A, Stichtenoth DO, et al. Myths and facts
in the use of anti-inflammatory drugs. Ann Med. 2009;41:
423--33.
34. Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and
bleeding events associated with rofecoxib in a 3-year col-
orectal adenoma chemoprevention trial. Gastroenterology.
2007;132:490--7.
35. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper
gastrointestinal ulcer bleeding associated with selective cyclo-
oxygenase-2 inhibitors, traditional non-aspirin non-steroidal
anti-inflammatory drugs, aspirin and combinations. Gut.
2006;55:1731--8.
36. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopido-
grel in addition to aspirin in patients with acute coronary
syndromes without ST-segment elevation. N Engl J Med.
2001;345:494--502.37. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopido-
grel to aspirin in 45,852 patients with acute myocardial
204  
infarction: randomised placebo-controlled trial. Lancet.
2005;366:1607--21.
38. Pfeffer MA, Jarcho JA. The charisma of subgroups and the
subgroups of CHARISMA. N Engl J Med. 2006;354:1744--6.
39. Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS,
et al. The fourth Mexican consensus on Helicobacter pylori.
Rev Gastroenterol Mex. 2018;83:325--41.
40. Anglin R, Yuan Y, Moayyedi P, et al. Risk of upper gastrointesti-
nal bleeding with selective serotonin reuptake inhibitors with
or without concurrent nonsteroidal anti-inflammatory use: a
systematic review and meta-analysis. Am J Gastroenterol.
2014;109:811--9.
41. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa
and dyspeptic symptoms in arthritic patients during chronic
steroidal anti-inflammatory drug use. Am J Gastroenterol.
1987;82:1153--8.
42. Ilone S, Simadibrata M. Diagnosis and management of gas-
troenteropathy associated to non-steroidal anti-inflammatory
drugs. Indon J Gastroenterol Hepatol Digest Endosc.
2016;17:116--23.
43. Moore A, Makinson G, Li C. Patient-level pooled analysis of
adjudicated gastrointestinal outcomes in celecoxib clinical tri-
als: meta-analysis of 51,000 patients enrolled in 52 randomized
trials. Arthritis Res Ther. 2013;15:R6.
44. Hernandez-Diaz S, Garcia-Rodríguez LA. Association between
nonsteroidal anti-inflammatory drugs and upper gastroin-
testinal tract bleeding/perforation. an overview of epidemi-
ologic studies published in the 1990s. Arch Intern Med.
2000;160:2093--9.
45. de Abajo FJ, García Rodríguez LA. Risk of upper gastrointesti-
nal bleeding and perforation associated with low-dose aspirin
as plain and enteric-coated formulations. BMC Clin Pharmacol.
2001;1:1.
46. Lanas A, García-Rodriguez LA, Polo-Tomas M, et al. Time
trends and impact of upper and lower gastrointestinal bleed-
ing and perforation in clinical practice. Am J Gastroenterol.
2009;104:1633--41.
47. Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of
mortality associated with hospital admission due to severe
gastrointestinal events and those associated with nons-
teroidal antiinflammatory drug use. Am J Gastrooenterol.
2005;100:1685--93.
48. Lanas A. A review of the gastrointestinal safety data----a
gastroenterologist’s perspective. Rheumatology (Oxford).
2010;49:ii3--10.
49. Lanas A, Scarpignato C. Microbial flora in NSAID-induced
intestinal damage: a role for antibiotics? Digestion.
2006;73:136--50.
50. Watanabe T, Tanigawa T, Nadatani Y, et al. Risk factors
for severe nonsteroidal anti-inflammatory drug-induced small
intestinal damage. Dig Liv Dis. 2013;45:390--5.
51. Graham DY, Opekun AR, Willingham FF, et al. Visible
small-intestinal mucosal injury in chronic NSAID users. Clin
Gastroenterol Hepatol. 2005;3:55--9.
52. Sugimori S, Watanabe T, Tabuchi M, et al. Evaluation of small
bowel injury in patients with rheumatoid arthritis by capsule
endoscopy: effects of antirheumatoid arthritis drugs. Diges-
tion. 2008;78:208--13.
53. Endo H, Hosono K, Inamori M, et al. Characteristics of small
bowel injury in symptomatic chronic low-dose aspirin users:
the experience of two medical centers in capsule endoscopy.
J Gastroenterol. 2009;44:544--9.
54. Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-
steroidal anti-inflammatory drug-induced enteropathy
determined by double balloon endoscopy: a Japanese
multicenter study. Scand J Gastroenterol. 2008;43:
490--6.M.V.  Bielsa-Fernández  et  al.
55. Laine L, Smith R, Min K, et al. Systematic review: the
lower gastrointestinal adverse effects of non-steroidal anti-
inflammatory drugs. Aliment Pharmacol Ther. 2006;24:751--67.
56. Taki M, Oshima T, Tozawa K, et al. Analysis of risk factors for
colonic diverticular bleeding and recurrence. Medicine (Balti-
more). 2017;96:e8090.
57. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mech-
anism of nonsteroidal anti-inflammatory drug-induced clinical
relapse in patients with inflammatory bowel disease. Clin Gas-
troenterol Hepatol. 2006:196--202.
58. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of
nonsteroidal antiinflammatory drugs on inflammatory
bowel disease: a case-control study. Am J Gastroenterol.
2000;95:1949--54.
59. Bonner GF, Walczak M, Kitchen L, et al. Tolerance of nons-
teroidal antiinflammatory drugs in patients with inflammatory
bowel disease. Am J Gastroenterol. 2000;95:1946--8.
60. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial
of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in
inflammatory bowel disease-associated peripheral arthritis
and arthralgia. Aliment Pharmacol Ther. 2003;17:1371--80.
61. Moninuola OO, Milligan W, Lochhead P, et al. Systematic review
with meta-analysis: association between acetaminophen and
nonsteroidal anti-inflammatory drugs(NSAIDs) and risk of
Crohn’s disease and ulcerative colitis exacerbation. Aliment
Pharmacol Ther. 2018;47:1428--39.
62. Kameda N, Higuchi K, Shiba M, et al. A prospective, single-
blind trial comparing wireless capsule endoscopy and double-
balloon enteroscopy in patients with obscure gastrointestinal
bleeding. J Gastroenterol. 2008;43:434--40.
63. Yamamoto H, Sekine Y, Sato H, et al. Total enteroscopy with
a nonsurgical steerable double balloon method. Gastrointest
Endosc. 2001;53:216--20.
64. Hayashi Y, Yamamoto H, Kita H, et al. Non-steroidal
anti-inflammatory drug-induced small bowel injuries iden-
tified by double-balloon endoscopy. World J Gastroenterol.
2003;11:4861--4.
65. Maiden L. Capsule endoscopic diagnosis of nonsteroidal anti-
inflammatory drug-induced enteropathy. J Gastroenterol.
2009;19:64--71.
66. Sunada K, Yamamoto H. Double-balloon endoscopy: past,
present, and future. J Gastroenterol. 2009;44:1--12.
67. Carmona-Sánchez R, Gómez-Escudero O, Zavala-Solares M,
et al. Mexican consensus on dyspepsia. Rev Gastroenterol Mex.
2017;82:309--27.
68. ASGE Standards of Practice Committee, Shaukat A, Wang A,
et al. The role of endoscopy in dyspepsia. Gastrointest Endosc.
2015;82:227--32.
69. Lau WY, Fan ST, Wong SH, et al. Preoperative and intraopera-
tive localisation of gastrointestinal bleeding of obscure origin.
Gut. 1987;28:869--77.
70. Longstreth GF. Epidemiology and outcome of patients hos-
pitalized with acute lower gastrointestinal hemorrhage: a
population-based study. Am J Gastroenterol. 1997;92:419--24.
71. Pasha SF, Leighton JA, Das A, et al. Double-balloon enteroscopy
and capsule endoscopy have comparable diagnostic yield in
small-bowel disease: a meta-analysis. Clin Gastroenterol Hep-
atol. 2008;6:671--6.
72. Gerson LB, Fidler JL, Cave DR, et al. ACG Clinical Guideline:
diagnosis and management of small bowel bleeding. Am J Gas-
troenterol. 2015;110:1265--87.
73. Gill RS, Kaffes AJ. Small bowel stricture characterization
and outcomes of dilatation by double-balloon enteroscopy:
a single-centre experience. Therap Adv Gastroenterol.
2014;7:108--14.
74. Baars JE, Theyventhiran R, Aepli P, et al. Double-balloon
enteroscopy-assisted dilatation avoids surgery for small bowel
vent
1
1
1
1
1
1
1
1The  Mexican  consensus  on  the  diagnosis,  treatment,  and  pre
strictures: a systematic review. World J Gastroenterol.
2017;23:8073--81.
75. Bjarnason I, Williams P, So A, et al. Intestinal permeability and
inflammation in rheumatoid arthritis: effects of non-steroidal
anti-inflammatory drugs. Lancet. 1984;2:1171--4.
76. Davies NM. Review article: non-steroidal anti-inflammatory
drug-induced gastrointestinal permeability. Aliment Pharma-
col Ther. 1998;12:303--20.
77. Tachecí I, Kopácová M, Rejchrt S, et al. Non-steroidal anti-
inflammatory drug induced injury to the small intestine. Acta
Medica (Hradec Kralove). 2010;53:3--11.
78. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention
of ulcers by esomeprazole in at-risk patients using non-
selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol.
2006;101:701--10.
79. Cannon CP, Curtis SP, Fitzgerald GA, et al. Cardiovascu-
lar outcomes with etoricoxib and diclofenac in patients
with osteoarthritis and rheumatoid arthritis in the Multi-
national Etoricoxib and Diclofenac Arthritis Long-term
(MEDAL) programme: a randomised comparison. Lancet.
2006;368:1771--81.
80. Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose com-
bination of enteric-coated naproxen and immediate-release
esomeprazole has comparable efficacy to celecoxib for knee
osteoarthritis: two randomized trials. Curr Med Res Opin.
2011;27:1243--53.
81. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus
omeprazole and diclofenac in patients with osteoarthritis and
rheumatoid arthritis (CONDOR): a randomised trial. Lancet.
2010;376:173--9.
82. White WB, West CR, Borer JS, et al. Risk of cardiovascular
events in patients receiving celecoxib: a meta-analysis of ran-
domized clinical trials. Am J Cardiol. 2007;99:91--8.
83. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular
risk of celecoxib in 6 randomized placebo-controlled tri-
als: the cross trial safety analysis. Circulation. 2008;117:
2104--13.
84. Coxib and traditional NSAID Trialists (CNT) Collaboration, Bhala
N, Emberson J, Merhi A, et al. Vascular and upper gas-
trointestinal effects of non-steroidal anti-inflammatory drugs:
meta-analyses of individual participant data from randomised
trials. Lancet. 2013;382:769--79.
85. Brereton N, Winn B, Akehurst R. The cost-effectiveness of cele-
coxib vs diclofenac in the treatment of osteoarthritis in the UK;
an update to the NICE model using data from the CONDOR trial.
J Med Econ. 2012;15:465--72.
86. Yang M, He M, Zhao M, et al. Proton pump inhibitors for
preventing non-steroidal anti-inflammatory drug induced gas-
trointestinal toxicity: a systematic review. Curr Med Res Opin.
2017;33:973--80.
87. Yeomans ND, Tulassay Z, Juhasz L, et al. Comparison of
omeprazole with ranitidine for ulcers associated with non-
steroidal antiinflammatory drugs. Acid Suppression Trial:
Ranitidine versus Omeprazole for NSAID-associated Ulcer
Treatment (ASTRONAUT) Study Group. N Eng J Med.
1998;338:719--26.
88. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention
in long-term users of nonsteroidal anti-inflammatory drugs:
results of a double-blind, randomized, multicenter, active- and
placebo-controlled study of misoprostol vs lansoprazole. Arch
Intern Med. 2002;162:169--75.
89. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omepra-
zole compared with misoprostol for ulcers associated with
nonsteroidal antiinflammatory drugs. Omeprazole versus Miso-
prostol for NSAID-induced Ulcer Management (OMNIUM) Study
Group. N Engl J Med. 1998;338:727--34.
90. Stupnicki T, Dietrich K, González-Carro P, et al. Efficacy and
tolerability of pantoprazole compared with misoprostol for
1ion  of  NSAID-induced  gastropathy  and  enteropathy  205
the prevention of NSAID-related gastrointestinal lesions and
symptoms in rheumatic patients. Digestion. 2003;68:198--208.
91. Jensen DM, Ho S, Hamamah S, et al. A randomized study of
omeprazole compared to misoprostol for prevention of recur-
rent ulcers and ulcer hemorrhage in high risk patients ingesting
aspirin or NSAIDs [abstract]. Gastroenterology. 2000;118. AGA
A892.
92. Valentini M, Cannizzaro R, Poletti M, et al. Nonsteroidal
antiinflammatory drugs for cancer pain: comparison between
misoprostol and ranitidine in prevention of upper gastrointesti-
nal damage. J Clin Oncol. 1995;13:2637--42.
93. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage
in the prevention of nonsteroidal anti-inflammatory drug-
induced gastric and duodenal ulcers: a comparison of three
regimens. Ann Intern Med. 1995;123:344--50.
94. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-
induced gastroduodenal ulcers. Cochrane Database Syst Rev.
2002:CD002296.
95. Yuan JQ, Tsoi KKF, Yang M, et al. Systematic review with
network meta-analysis: comparative effectiveness and safety
of strategies for preventing NSAID-associated gastrointestinal
toxicity. Aliment Pharmacol Ther. 2016;43:1262--75.
96. Cryer B, Li C, Simon LS, et al. GI-REASONS: a novel
6-month, prospective, randomized, open- label, blinded
endpoint (PROBE) trial. Am J Gastroenterol. 2013;108
:392--400.
97. Moore A, Makinson G, Li C. Patient-level pooled analysis of
adjudicated gastrointestinal outcomes in celecoxib clinical tri-
als: meta-analysis of 51,000 patients enrolled in 52 randomized
trials. Arthritis Res Ther. 2013;15:R6.
98. Capone ML, Sciulli MG, Tacconelli S. y cols. Pharmacodynamic
interaction of naproxen with low-dose aspirin in healthy sub-
jects. J Am Coll Cardiol. 2005;45:1295--301.
99. Wallace JL, Denou E, Vong L, et al. Proton pump inhibitors
and low-dose aspirin markedly exacerbate NSAID-induced
small intestinal injury: a link to dysbiosis? Gastroenterology.
2011;140:S-87.
00. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy
to prospectively assess small bowel injury with celecoxib,
naproxen plus omeprazole, and placebo. Clin Gastroenterol
Hepatol. 2005;3:133--41.
01. Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative
analysis of NSAID-induced small bowel pathology by capsule
endoscopy. Gastroenterology. 2005;128:1172--8.
02. Fujimora S, Gudis K, Takahashi Y, et al. Distribution of small
intestinal mucosal injuries as a result of NSAID administration.
Eur J Clin Invest. 2010;40:504--10.
03. Lanza FL, Chan FKL, Quigley EMM, et al. Guidelines for
Prevention of NSAID-Related Ulcer Complications. Am J Gas-
troenterol. 2009;104:728--38.
04. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori
infection and non-steroidal anti-inflammatory drugs in peptic-
ulcer disease: a meta-analysis. Lancet. 2002;359:14--22.
05. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of
eradication of Helicobacter pylori before non-steroidal anti-
inflammatory drug therapy to prevent peptic ulcers. Lancet.
1997;350:975--9.
06. Chan FK, To KF, Wu  JC, et al. Eradication of Helicobacter pylori
and risk of peptic ulcers in patients starting long-term treat-
ment with nonsteroidal anti-inflammatory drugs: a randomised
trial. Lancet. 2002;359:9--13.
07. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Heli-
cobacter pylori on the prevention of gastroduodenal ulcers in
patients receiving long-term NSAIDs: a double-blind, placebo-
controlled trial. Aliment Pharmacol Ther. 2003;17:799--805.08. de Leest HT, Steen KS, Lems WF, et al. Eradication of
Helicobacter pylori does not reduce the incidence of gastro-
duodenal ulcers in patients on long-term NSAID treatment:
21
1
1
1
1
1
1
1
1
1
106  
double-blind, randomized, placebo-controlled trial. Heli-
cobacter. 2007;12:477--85.
09. Watanabe T, Nishio H, Tanigawa T, et al. Probiotic Lactobacil-
lus casei strain Shirota prevents indomethacin-induced small
intestinal injury: involvement of lactic acid. Am J Physiol Gas-
trointest Liver Physiol. 2009;297:G506--13.
10. Montalto M, Gallo A, Curigliano V, et al. Clinical trial:
the effects of a probiotic mixture on non-steroidal anti-
inflammatory drug enteropathy: a randomized, double-blind,
cross-over, placebo-controlled study. Aliment Pharmacol Ther.
2010;32:209--14.
11. Park SH, Cho CS, Lee OY, et al. Comparison of prevention of
NSAID-induced gastrointestinal complications by rebamipide
and misoprostol: a randomized, multicenter, controlled trial
- STORM STUDY. J Clin Biochem Nutr. 2007;40:148--55.
12. Terano A, Arakawa T, Sugiyama T, et al. Rebamipide, a gastro-
protective and anti-inflammatory drug, promotes gastric
ulcer healing following eradication therapy for Helicobacter
pylori in a Japanese population: a randomized, double-blind,
placebo-controlled trial. J Gastroenterol. 2007;42:690--3.13. Kim HK, Kim JI, Kim JK, et al. Preventive effects of rebamipide
on NSAID-induced gastric mucosal injury and reduction of gas-
tric mucosal blood flow in healthy volunteers. Dig Dis Sci.
2007;52:1776--82.M.V.  Bielsa-Fernández  et  al.
14. Kent TH, Cardelli RM, Stamler FW.  Small intestinal ulcers
and intestinal flora in rats given indomethacin. Am J Pathol.
1969;54:237--49.
15. Sakurai K, Sasabe H, Koga T, et al. Mechanism of hydroxyl
radical scavenging by rebamipide: identification of mono-
hydroxylated rebamipide as a major reaction product. Free
Radic Res. 2004;38:487--94.
16. Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An
open-labeled study of rebamipide treatment in chronic gas-
tritis patients with dyspeptic symptoms refractory to proton
pump inhibitors. Dig Dis Sci. 2008;53:2896--903.
17. Mizukami K, Murakami K, Abe T, et al. Aspirin-induced small
bowel injuries and the preventive effect of rebamipide. World
J Gastroenterol. 2011;17:5117--22.
18. Kurokawa S, Katsuki S, Fujita T, et al. A randomized, double-
blinded, placebo-controlled, multicenter trial, healing effect
of rebamipide in patients with low-dose aspirin and/or non-
steroidal anti-inflammatory drug induced small bowel injury. J
Gastroenterol. 2014;49:239--44.
19. Laine L, Curtis SP, Langman M, et al. Lower gastrointesti-
nal events in a double-blind trial of the cyclo-oxygenase-2
selective inhibitor etoricoxib and the traditional nons-
teroidal anti-inflammatory drug diclofenac. Gastroenterology.
2008;135:1517--25.
